$ONTX Someone probably mentioned this here already but I think 1- Company is trying to keep the price above $1 for compliance otherwise they would have done an offering to cover cost for covid-19. 2- Rigosertib is already a well known, working drug and I think during RAS phase 3 , they probably treat a patient with covid-19. They know it works. 3- Phase 3 PR will be epic because they keep pushing the results back , the idea that the subjects are not dying because of Rigosertib might actually be true 4- If Company gets funding and the drug actually works and phase 3 is positive, I see a price target of at least $30
  • 16
16 Likes